Research community

🔥 Hot Today in Peptide Research

October 8, 2026

Last updated October 8, 2026, 08:44 Israel time

6 stories were heating up that day

🔥🔥🔥

Report: plans would allow temporary sale of some restricted peptides

Mountaineer on a snowy ridge under a cloudy sky

Photo: Danka & Peter / StockSnap (CC0) / own upload

The Washington Post reported on 7 October that the administration is crafting plans that would allow the temporary sale of certain previously restricted peptides while federal health officials work out new regulations for the products, citing two people familiar with the matter. The newspaper also noted that FDA scientists and some medical experts have raised concerns about increasing access to certain peptides. The report describes plans still being drawn up; it is not a published FDA notice or rule.

The Washington PostFDA Watch

For research-community awareness only. Not legal advice.

🔥🔥

Tunable glycine chemistry singles out Staphylococcus aureus

Photo: Vidsplay / StockSnap (CC0) / own upload

Researchers at IISER Bhopal and collaborating institutes reported in Nature Communications on 5 October an electronically tunable chemical method that selectively modifies N-terminal glycine. Because S. aureus carries a pentaglycine signature in its cell wall, the method allowed species-specific detection of the bacterium and its resistant strains, and labelled it in fruit flies and in mouse infection models. The authors also report inhibition of clinical strains and biofilms in laboratory tests; the work is preclinical.

Nature CommunicationsResearch Buzz

Read the Full Update

🔥🔥

Peptide coatings tune lipid nanoparticles for mRNA delivery

Cluster of glowing blue and violet light orbs

Photo: asim alnamat / StockSnap (CC0) / own upload

A Tianjin University team reported in Biomacromolecules, published online on 6 October, a way to modify lipid nanoparticles after formulation by coating them with modular multifunctional peptides through physical assembly. In cell experiments the coatings increased cellular uptake, endosomal escape and mRNA translation, and in animal experiments optimised coatings improved mRNA delivery across several LNP formulations. The results are preclinical.

BiomacromoleculesResearch Buzz

Read the Full Update

🔥

Machine-learning screen finds a polypeptide that dampens TLR9 signalling

Blue light ribbons flaring outward on a dark background

Photo: Vidsplay / StockSnap (CC0) / own upload

The Journal of the American Chemical Society published on 7 October a study from researchers in China, including Peking University, that combined high-throughput synthesis and screening with machine-learning-assisted optimisation of random hybrid polypeptides. The lead polypeptide, IDP-IMP, suppressed CpG DNA–TLR9 signalling with limited cytotoxicity through moderate, multivalent interactions rather than strong binding, and lowered inflammation and joint pathology in a rat arthritis model. The work is preclinical.

Journal of the American Chemical SocietyResearch Buzz

🔥

Aragen opens a peptide and ADC platform in Hyderabad

Lanes of an outdoor stadium running track

Photo: Mateusz Dach / StockSnap (CC0) / own upload

ETPharma reported on 6 October that Aragen Life Sciences has brought into operation Aragen OneHP, an integrated development and manufacturing platform for peptides and antibody-drug conjugates at its Nacharam campus in Hyderabad, India. The platform adds capabilities for highly potent molecules and an active-ingredient manufacturing line with an annual capacity of 500 to 600 kg.

ETPharmaIndustry

Read the Full Update

🔥

Ofichem to acquire New York CDMO Kinentia Biosciences

Mountaineers crossing a sunny highland valley

Photo: Michal Parzuchowski / StockSnap (CC0) / own upload

Contract Pharma reported on 7 October that Ofichem has agreed to acquire Kinentia Biosciences, a drug-substance contract manufacturer in Rensselaer, New York. According to the report, the deal adds expertise in small peptides, polysaccharides and complex new chemical entities, and after completion Ofichem's drug-substance business will operate across New York, Ter Apel in the Netherlands and Uppsala in Sweden.

Contract PharmaIndustry

Read the Full Update

🔥🔥🔥

Peptide 'bait' quiets pain-signalling neurons in mouse models

Violet lightning branching across a dark night sky

Photo: Jeremy Thomas / StockSnap (CC0) / own upload

Boston Children's Hospital reported on 6 October on a study in Cell Reports Medicine showing that the sodium channel NaV1.8 in pain-sensing neurons relies on the scaffolding protein ankyrin-G (Ank3) to sustain the heightened activity seen in pathological pain. A short lipidated peptide (SLiP) that disrupts this interaction lowered NaV1.8 levels in the cell membrane and reduced pain-like behaviours in mouse models, while acute protective pain was spared. The work is preclinical, and the intellectual property has been licensed to a Boston biotechnology company.

EurekAlert! (Boston Children's Hospital)Research

🔥🔥

Catalytic ring closure builds atropisomeric cyclic peptides

Orange and charcoal 3D swirl of curved ribbons

Photo: Altered Reality / StockSnap (CC0) / own upload

IOCB Prague reported on 5 October on a paper in Angewandte Chemie describing a catalytic intramolecular SNAr macrocyclization in which a fluoride catalyst works with an organosilane to form sterically hindered carbon–nitrogen bonds. The method closed linear precursors directly into strained medium-sized rings and macrocycles, and with tryptophan-containing peptides it gave structurally diverse 'atropopeptides' inspired by natural RiPPs. The institute says the new cyclic peptides will next go into bioactivity screening.

IOCB PragueResearch

🔥🔥

SK pharmteco plans a $200M+ US build-out that includes peptides

Skateboarder upside down at the lip of a skate bowl at sunset

Photo: Willian Was / StockSnap (CC0) / own upload

BioSpectrum Asia reported on 6 October that SK pharmteco, a subsidiary of South Korea's SK Inc., plans a five-year investment of more than $200 million in its US development and manufacturing infrastructure for small molecules and peptides. The plan includes new development laboratories, new GMP kilo-scale peptide capacity scheduled to be operational in late 2026 alongside advanced liquid chromatography, new manufacturing suites and about 100 long-term US jobs.

BioSpectrum AsiaIndustry

🔥

CordenPharma adds peptide synthesis at its South Carolina site

Photo: Tommy Lisbin / StockSnap (CC0) / own upload

WJBF reported, in a story updated on 5 October, that CordenPharma is expanding its Aiken County, South Carolina site, previously operated by AmbioPharm, to add peptide synthesis to the purification and quality-control work already done there, so customers can go from synthesis through purification at one location. The company expects more than 200 new jobs, a larger hiring push from the third quarter of 2027, and the expansion to be operational in 2027.

WJBFIndustry

🔥

Computer search for tetrapeptide catalysts gets under way in Texas

Dense web of fine white and teal light filaments on a dark background

Photo: Vidsplay / StockSnap (CC0) / own upload

Southwest Research Institute said on 6 October that it will work with The University of Texas at San Antonio to identify tetrapeptide catalysts using SwRI's Rhodium molecular docking platform, the first time the platform will be used to find catalysts rather than drug candidates. SwRI will supply computational data and a list of candidate peptide catalysts, which UT San Antonio researchers will then test and validate in their laboratories. The aim is more efficient synthesis of organic molecules; the project itself will not advance any medicine.

EurekAlert! (Southwest Research Institute)Research

🔥

Engineered bacterial nanomachine carries antimicrobial peptides into infected immune cells

Glowing blue 3D render of round microbes with teal clusters

Photo: Bango Renders / StockSnap (CC0) / own upload

BioCentury reported on 6 October on a study from the Chinese Academy of Medical Sciences and Peking Union Medical College in which researchers engineered a bacterial contractile nanomachine (an eCIS derived from the Photorhabdus virulence cassette) to carry mycobacteriophage-derived antimicrobial peptides and bind the CD11b receptor on alveolar macrophages. The system inhibited intracellular mycobacteria in lab tests, including drug-sensitive and isoniazid-resistant M. tuberculosis, and lowered lung bacterial burden by more than tenfold in infected mice.

BioCenturyResearch

Curated for research-community awareness. Not medical or legal advice. All products on this site are for laboratory research use only.